Treat knee cartilage lesions and osteochondral defects in a single-stage procedure, even in the presence of mild to moderate osteoarthritis (Kellgren-Lawrence 0-3),1,2 with the porous, biocompatible CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant; shown to be clinically superior to the current surgical standard of care in level 1 clinical data.*1,2
The need for knee cartilage repair is expected to grow,4 with articular cartilage injuries already observed in 60-66% of knee arthroscopies5-7 and knee cartilage repair procedures projected to increase through 2031.4 However, conventional approaches currently result in an average 1 in 4 patients not returning to sport.**8 Furthermore, many patients treated with microfracture return to the operating room.***9
As an alternative to conventional surgical repair methods, the CARTIHEAL Implant is a naturally occurring, biomaterial scaffold that helps repair cartilage and restore bone;1-3,10-14 shown to result in a significantly greater improvement in overall KOOS scores*1,2 and reduced the risk of total knee arthroplasty or osteotomy by 87%.****1
Designed for off-the-shelf convenience, the procedure can be carried out in a single stage without any additional preparation of the implant.
Click the link below to learn more about the CARTIHEAL Implant.
After implantation, the CARTIHEAL Implant has a distinct, two-phase mode of action.
In the bone phase, mesenchymal stem cells (MSCs) adhere and differentiate into osteogenic cells, which form new bone (demonstrated in vitro).12
In the cartilage phase, a modified porosity helps MSCs differentiate into chondrocytes. On the surface, chondrocyte cells migrate from the surrounding native cartilage and form new cartilage (demonstrated in vitro and in vivo).10,14,16,17
* Compared to the surgical standard of care (microfracture or debridement) at 2- and 4-year follow-up.
** Average return to sport demonstrated in a meta-analysis examining patients treated with microfracture, osteochondral allograft transplantation, autologous chondrocyte implantation and osteochondral autograft transfer. Performance of specific procedure may vary.
*** ~35% and ~40% required additional procedures related to the articular cartilage 4 and 10 years after microfracture
**** Compared to the surgical standard of care (microfracture or debridement) at 4-year follow-up.
Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product’s applicable Instructions for Use (IFU) prior to use.
Text